David Schaer PhD serves as Senior Director and Bayer Science Fellow in Immuno-Oncology Precision Medicine at Bayer since May 2022, leading the DGK program and representing Bayer in the IMMUcan consortium. Previously, David held the position of Director and Translational Oncology Lead at Pfizer from February 2019 to May 2022, where responsibilities included contributing to early-phase clinical asset development and establishing clinical research collaborations. At Eli Lilly from April 2014 to February 2019, David was Principal Research Scientist in Cancer Immunobiology, spearheading combination immunotherapy research and bi-specific clinical programs. David's earlier experience includes a role as Senior Research Scientist at Memorial Sloan Kettering Cancer Center from 2005 to 2014, focusing on immuno-oncology clinical biomarker discovery and drug development, along with a postdoctoral fellowship at the same institution. Educational qualifications include a PhD in Biomedical Sciences from New York University and a BS in Biology with High Honors from Brandeis University.
This person is not in the org chart
This person is not in any teams
This person is not in any offices